📊 Glenmark Pharma – Technical & Fundamental View

Technical Outlook: After a sharp rally to ₹2,384 in July, Glenmark saw a healthy correction but has now resumed its uptrend. Price has rebounded strongly from the ₹1,900 support zone and is trading above its 20/50-day EMAs (~₹2,000), showing renewed momentum. RSI has bounced back to ~66, indicating strength without being in the overbought zone. Volumes on recent up days confirm buying interest. Immediate resistance lies near ₹2,250–₹2,300; a breakout above ₹2,300 can open fresh upside towards ₹2,450–₹2,500. Key support stays at ₹1,950–₹2,000. Fundamental Outlook: Glenmark’s strong Q1FY26 results (profit up ~34% YoY, margin expansion, robust domestic formulation growth) have boosted confidence. The company continues to focus on specialty & innovative therapies, APIs, and emerging markets, which provide earnings visibility. Its strategic demerger of Glenmark Life Sciences unlocks value and helps reduce debt. Rising global demand for respiratory and dermatology drugs further adds tailwinds. Short-Term View: Bullish bias; can test ₹2,250–₹2,300 with stop loss near ₹1,950. Long-Term View: Positive, backed by growth visibility, strong pipeline, and balance sheet improvement. Potential upside of 15–20% over 12–18 months if earnings momentum sustains. ⚠️ Risk: Regulatory hurdles, USFDA observations, and forex volatility remain key risks to monitor.